Enzyme Linked Immunosorbent Assay (ELISA)
Approximately 75-80% of patients have serum autoantibodies to the M-type phospholipase A2 receptor (PLAR2). In contrast, less than 10% of patients with secondary membranous nephropathy, other forms of glomerulonephritis, as well as healthy individuals are positive for autoantibody to the PLA2R antibody. An increase, decrease or disappearance generally precedes a change in the clinical status, thus the antibody titer has a predictive value with respect to clinical remission, relapse, or risk assessment after kidney transplantation. A test for colocalization of PLA2R and IgG4 of kidney tissue is recommended in seronegative samples to confirm or exclude a diagnosis of PLA2R antibody-mediated MGN.
Positive: >20 U/mL Borderline: 14 to 20 U/mL Negative: <14 U/mL.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
7 - 10 days
- Anti-Phospholipase A2 Receptor Antibody
- Phospholipase A2 Receptor Autoantibody
Test sent to Cincinnati Children’s Hospital.